Hydrochloric Acid

Hydrochloric Acid

SCHEMBL924823

Cl.N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)O

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ ACE known ✓ P12821 2/20 0.44
▸ OPRM1 known ✓ P35372 2/20 0.42
▸ OPRD1 known ✓ P41143 3/20 0.42
▸ SLC7A5 Q01650 1/20 0.47
▸ YARS1 P54577 2/20 0.47
▸ MME P08473 2/20 0.46
▸ CPA1 P15085 1/20 0.43
▸ ACE2 Q9BYF1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL20335514 1.00 SLC7A5 (0.47) SLC7A5YARS1MMEACECPA1
SCHEMBL23598458 0.99 SLC7A5 (0.48) SLC7A5YARS1MMEACECPA1
SCHEMBL4434130 0.99 SLC7A5 (0.48) SLC7A5YARS1MMEACECPA1
SCHEMBL9665005 0.99 SLC7A5 (0.48) SLC7A5YARS1MMEACECPA1
SCHEMBL4434143 0.99 SLC7A5 (0.48) SLC7A5YARS1MMEACECPA1
SCHEMBL9664998 0.99 SLC7A5 (0.48) SLC7A5YARS1MMEACECPA1
SCHEMBL31553196 0.97 YARS1 (0.46) SLC7A5YARS1MMEOPRM1OPRD1
SCHEMBL31006409 0.96 MME (0.47) SLC7A5YARS1MMEACEOPRM1
SCHEMBL38650869 0.96 MME (0.47) SLC7A5YARS1MMEACEOPRM1
SCHEMBL31259944 0.96 MME (0.47) SLC7A5YARS1MMEACEOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4326892-A1 METHOD FOR SELECTING ECOBIOLOGICAL TOPICAL COMPOSITIONS AND INGREDIENTS CAPABLE OF RESTORING OR REINFORCING THE SKIN MICROBIOTA NAOS Institute of Life Science (FR) 2024-02-28 — — EP claimed
WO-2022223928-A1 METHOD FOR SELECTING ECOBIOLOGICAL TOPICAL COMPOSITIONS AND INGREDIENTS CAPABLE OF RESTORING OR REINFORCING THE SKIN MICROBIOTA NAOS INSTITUTE OF LIFE SCIENCE (FR) 2022-10-27 — — WO claimed
US-20210244635-A1 ENZYMATIC MOLECULE MIMICKING ANTI-OXIDANT ACTIVITY BIONUCLEI (FR) 2021-08-12 — — US claimed
EP-3801058-A1 ENZYMATIC MOLECULE MIMICKING ANTI-OXIDANT ACTIVITY Bionuclei (FR) 2021-04-14 — — EP claimed
US-20120171156-A1 METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES HDS LTD. (GB) 2012-07-05 — — US claimed
EP-2442873-A2 METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES Hds Limited (GB) 2012-04-25 — — EP claimed
WO-2010146142-A9 METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES HDS LIMITED (GB) 2011-06-16 — — WO claimed
WO-2010146142-A2 METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES HDS LIMITED (GB) 2010-12-23 — — WO claimed
WO-2026104886-A1 METHOD FOR EXTRACTING LOW-MOLECULAR WEIGHT COLLAGEN USING POLLACK SKIN, LOW-MOLECULAR WEIGHT COLLAGEN, AND COSMETIC COMPOSITION COMPRISING SAME WITH SKIN REGENERATION EFFICACY 유엔케이코리아 주식회사 2026-05-21 — — WO disclosed
EP-4326892-A1 METHOD FOR SELECTING ECOBIOLOGICAL TOPICAL COMPOSITIONS AND INGREDIENTS CAPABLE OF RESTORING OR REINFORCING THE SKIN MICROBIOTA NAOS Institute of Life Science (FR) 2024-02-28 — — EP disclosed
US-11904037-B2 Enzymatic molecule mimicking anti-oxidant activity BIONUCLEI (FR) 2024-02-20 — — US disclosed
CN-112512641-B Method for local protection of free radical and/or atmospheric contaminant molecules generated by exposure to ultraviolet radiation 比奥尼克莱公司 2023-12-19 — — CN disclosed
US-11801208-B2 Method for topical protection against atmospheric pollutant molecules and/or free radicals produced by exposure to ultraviolet radiation BIONUCLEI (FR) 2023-10-31 — — US disclosed
CN-116490598-A Detergent compositions with enhanced efficacy delivery of substances 株式会社LG生活健康 2023-07-25 — — CN disclosed
WO-2010146142-A2 METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES HDS LIMITED (GB) 2010-12-23 — — WO disclosed
US-20100143274-A1 USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS CIBA CORPORATION (US) 2010-06-10 — — US disclosed
WO-2010056233-A1 COMPOSITION WITH A COLOR TO INDICATE COVERAGE COLGATE-PALMOLIVE COMPANY (US) 2010-05-20 — — WO disclosed
WO-2010056232-A1 COMPOSITION WITH A COLOR MARKER COLGATE PALMOLIVE COMPANY (US) 2010-05-20 — — WO disclosed
EP-2120846-A2 USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS BASF SE (DE) 2009-11-25 — — EP disclosed
WO-2008107347-A2 USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS BASF SE (CH) 2008-09-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143274-A1 USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS MAOA, MAOB, ACMSD ACE 2813/4885OPRM1 385/4885OPRD1 1952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback